Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck?

Nature Clinical Practice Oncology volume 4, pages 690–691 (2007)Cite this article

boxed-textVermorken JB et al. (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171–2177

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Forastiere AA et al. (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group (SWOG) study. J Clin Oncol 10: 1245–1251

    Article  CAS  Google Scholar 

  2. Cunningham D et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345

    Article  CAS  Google Scholar 

  3. Forastiere AA (2007) Epidermal growth factor receptor inhibition in head and neck cancer—more insights, but more questions. J Clin Oncol 25: 2152–2155

    Article  Google Scholar 

  4. Vokes EE et al. (2005) A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 23 (Suppl 16): S501

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. JA Bonner is the Merle M Salter Professor and Chairman of the Department of Radiation Oncology, and KS Keene is an Assistant Professor in the Department of Radiation Oncology, University of Alabama, Birmingham, AL, USA.,

    James A Bonner & Kimberly S Keene

Authors
  1. James A Bonner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimberly S Keene
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James A Bonner.

Ethics declarations

Competing interests

JA Bonner has acted as a consultant for and has received speakers' bureau honoraria from the following companies: Bristol-Myers Squibb and ImClone Systems. KS Keene declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonner, J., Keene, K. Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck?. Nat Rev Clin Oncol 4, 690–691 (2007). https://doi.org/10.1038/ncponc0962

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0962

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing